Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664387 | 0.91 | BACE1 (0.53) | BACE1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3661573 | 0.88 | BACE1 (0.49) | BACE1 | |
| SCHEMBL9872721 | 0.86 | CYP2D6 (0.47) | BACE1CYP2D6HTR2AHTR2C | |
| SCHEMBL11795167 | 0.86 | SLC6A4 (0.56) | BACE1HTR2AHTR2C | |
| SCHEMBL3663874 | 0.85 | SLC6A9 (0.53) | BACE1 | |
| SCHEMBL14282941 | 0.84 | PRCP (0.54) | BACE1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3661505 | 0.83 | BACE1 (0.45) | BACE1KDM4E | |
| SCHEMBL14282927 | 0.83 | BACE1 (0.52) | BACE1KDM4ETSHRNPC1 | |
| SCHEMBL3661510 | 0.82 | BACE1 (0.48) | BACE1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11791324 | 0.81 | HTR2A (0.61) | BACE1KDM4ECYP2D6TSHRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1443929-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2003032912-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1443929-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | BACE1 1442/4885KDM4E 331/4885CYP1A2 512/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | BACE1 1442/4885KDM4E 331/4885CYP1A2 512/4885 |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | SLC18A2, SLC7A11, SLC6A5 | BACE1 201/4885KDM4E 3389/4885CYP1A2 993/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | BACE1 1266/4885KDM4E 275/4885CYP1A2 612/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | BACE1 1227/4885KDM4E 268/4885CYP1A2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.